AI assistant
REPLIGEN CORP — Director's Dealing 2026
Jan 12, 2026
30826_dirs_2026-01-12_f8bd5439-8fa5-4285-86d4-4a1ff2be7067.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: REPLIGEN CORP (RGEN)
CIK: 0000730272
Period of Report: 2025-12-31
Reporting Person: Douglass Brian Robb (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | Common Stock | A | 2288 | $0.00 | Acquired | 8540 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Stock Option (Right to Buy) | $163.86 | A | 2143 | Acquired | 2035-12-31 | Common Stock (2143) | Direct |
Footnotes
F1: Mr. Douglass was awarded 2,288 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in substantially equal annual instalments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock.
F2: The shares will vest in substantially equal installments over a three-year period with each such vesting date occurring on the anniversary of the grant date.